guest ::
| Home > Publications database > ADCK2 Knockdown Affects the Migration of Melanoma Cells via MYL6. > print |
| Home > Publications database > ADCK2 Knockdown Affects the Migration of Melanoma Cells via MYL6. > print |
| 001 | 178948 | ||
| 005 | 20240229143600.0 | ||
| 024 | 7 | _ | |a 10.3390/cancers14041071 |2 doi |
| 024 | 7 | _ | |a pmid:35205819 |2 pmid |
| 037 | _ | _ | |a DKFZ-2022-00364 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Vierthaler, Marlene |0 P:(DE-He78)61de47f47323d5d0b1700e8213e5179f |b 0 |e First author |u dkfz |
| 245 | _ | _ | |a ADCK2 Knockdown Affects the Migration of Melanoma Cells via MYL6. |
| 260 | _ | _ | |a Basel |c 2022 |b MDPI |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1646048828_2804 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a #EA:A370#LA:A370# |
| 520 | _ | _ | |a ADCK2 is a member of the AarF domain-containing kinase family, which consists of five members, and has been shown to play a role in CoQ metabolism. However, ADCKs have also been connected to cancer cell survival, proliferation and motility. In this study, we investigated the role of ADCK2 in melanoma.The effect of ADCK2 on melanoma cell motility was evaluated by a scratch assay and a transwell invasion assay upon siRNA-mediated knockdown or stable overexpression of ADCK2.We found that high levels of intratumoral ADCK2 and MYL6 are associated with a higher survival rate in melanoma patients. Knocking down ADCK2 resulted in enhanced cell migration of melanoma cells. Moreover, ADCK2-knockdown cells adopted a more dedifferentiated phenotype. A gene expression array revealed that the expression of ADCK2 correlated with the expressions of MYL6 and RAB2A. Knocking down MYL6 in ADCK2-overexpressing cells could abrogate the effect of ADCK2 overexpression and thus confirm the functional connection between ADCK2 and MYL6.ADCK2 affects melanoma cell motility, most probably via MYL6. Our results allow the conclusion that ADCK2 could act as a tumor suppressor in melanoma. |
| 536 | _ | _ | |a 311 - Zellbiologie und Tumorbiologie (POF4-311) |0 G:(DE-HGF)POF4-311 |c POF4-311 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de |
| 650 | _ | 7 | |a ADCK2 |2 Other |
| 650 | _ | 7 | |a MYL6 |2 Other |
| 650 | _ | 7 | |a cancer |2 Other |
| 650 | _ | 7 | |a melanoma |2 Other |
| 650 | _ | 7 | |a motility |2 Other |
| 700 | 1 | _ | |a Sun, Qian |0 P:(DE-He78)f1f0076fc72606659a5df2605acce91b |b 1 |u dkfz |
| 700 | 1 | _ | |a Wang, Yiman |0 P:(DE-He78)ada7e359a1f7451130dbc79595227bec |b 2 |u dkfz |
| 700 | 1 | _ | |a Steinfass, Tamara |0 P:(DE-He78)a65fa5fbdeff5a1bb6ee7de07b820488 |b 3 |u dkfz |
| 700 | 1 | _ | |a Poelchen, Juliane |0 P:(DE-He78)88a268b9173c651561385cddfdf819fa |b 4 |u dkfz |
| 700 | 1 | _ | |a Hielscher, Thomas |0 P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f |b 5 |u dkfz |
| 700 | 1 | _ | |a Novak, Daniel |0 P:(DE-He78)5f0b1c9863f44d0695555ee3c22b9758 |b 6 |u dkfz |
| 700 | 1 | _ | |a Umansky, Viktor |0 P:(DE-He78)38be34240daf8b47325afc7910e77f7b |b 7 |u dkfz |
| 700 | 1 | _ | |a Utikal, Jochen |0 P:(DE-He78)a229f7724466e7efadf4a1ace1ff8af3 |b 8 |e Last author |u dkfz |
| 773 | _ | _ | |a 10.3390/cancers14041071 |g Vol. 14, no. 4, p. 1071 - |0 PERI:(DE-600)2527080-1 |n 4 |p 1071 |t Cancers |v 14 |y 2022 |x 2072-6694 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:178948 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-He78)61de47f47323d5d0b1700e8213e5179f |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)f1f0076fc72606659a5df2605acce91b |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-He78)ada7e359a1f7451130dbc79595227bec |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-He78)a65fa5fbdeff5a1bb6ee7de07b820488 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 P:(DE-He78)88a268b9173c651561385cddfdf819fa |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 6 |6 P:(DE-He78)5f0b1c9863f44d0695555ee3c22b9758 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 7 |6 P:(DE-He78)38be34240daf8b47325afc7910e77f7b |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 8 |6 P:(DE-He78)a229f7724466e7efadf4a1ace1ff8af3 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-311 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Zellbiologie und Tumorbiologie |x 0 |
| 914 | 1 | _ | |y 2022 |
| 915 | _ | _ | |a Creative Commons Attribution CC BY (No Version) |0 LIC:(DE-HGF)CCBYNV |2 V:(DE-HGF) |b DOAJ |d 2021-05-04 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-05-04 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2021-05-04 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-05-04 |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2021-05-04 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2021-05-04 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b CANCERS : 2021 |d 2022-11-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2022-11-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2022-11-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2022-01-24T07:56:58Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2022-01-24T07:56:58Z |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Blind peer review |d 2022-01-24T07:56:58Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2022-11-30 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2022-11-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2022-11-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2022-11-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2022-11-30 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b CANCERS : 2021 |d 2022-11-30 |
| 920 | 2 | _ | |0 I:(DE-He78)A370-20160331 |k A370 |l KKE Dermatoonkologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)A370-20160331 |k A370 |l KKE Dermatoonkologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)C060-20160331 |k C060 |l C060 Biostatistik |x 1 |
| 920 | 0 | _ | |0 I:(DE-He78)A370-20160331 |k A370 |l KKE Dermatoonkologie |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)A370-20160331 |
| 980 | _ | _ | |a I:(DE-He78)C060-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|